There's more to young biopharma companies than their numbers, but those numbers are still an important part of each ...

This new technology could one day significantly expand the market for gene-editing biotechs.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 1.81% at $60.77. This change lagged the S&P 500's daily ...

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...

In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

The inventor of the groundbreaking Crispr gene-editing technology is skeptical about artificial intelligence replacing human ...

Biohub researchers performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, then used an AI model to mine ...

When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left – but then she was ...

The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates ...